Primary breast lymphoma: Patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study

Jeanneret‐Sozzi, Wendy; Taghian, Alphonse G.; Epelbaum, Ron; Poortmans, Philip; Zwahlen, Daniel R.; Amsler, Beat; Villette, S.; Belkacémi, Yazid; Nguyen, Tan Dat; Scalliet, Pierre; Maingon, P.; Gutiérrez, Cristina; Gastelblum, Pauline; Krengli, Marco; Raad, Rita Abi; Ozşahin, Mahmut; Mirimanoff, René-Olivier

doi:10.1186/1471-2407-8-86

Cited by 140 publications

(166 citation statements)

References 32 publications

Supporting

Mentioning

156

Contrasting

Order By: Relevance

“…Several collaborative investigations have been conducted to define the clinical characteristics of PBL and evaluate its management approaches (4,5,14). The criteria of PBL defined by Wiseman and Liao (15) were used in the majority of these studies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Primary breast lymphoma: A single center study

et al. 2016

View full text Add to dashboard Cite

Abstract. The aim of the present study was to summarize the clinical characteristics of primary breast lymphoma (PBL) and evaluate its management approaches. A total of 29 patients newly diagnosed with PBL, and treated between April 2006 and May 2013, were analyzed retrospectively. The median survival follow-up time for all patients was 66.8 (range, 25.4-110.0) months. The results of the follow-up revealed 22 living lymphoma-free patients and 7 patients who had succumbed to PBL. Of the 7 deceased patients, 6 had succumbed to lymphoma and 1 to chemotherapy-associated hepatic failure. In total, 1 patient who presented with bilateral breast lymphoma developed left breast relapse following lumpectomy and chemotherapy, 2 patients developed a bone marrow relapse, 1 patient developed lung and mediastinal lymph node relapses, and 1 patient developed a skin relapse. The Kaplan-Meier estimator predicted 5-year overall survival and progression-free survival rates for all patients of 74.4 and 74.6%, respectively. PBL appears to be a rare disease with a good overall prognosis and low incidence of local relapse, following chemotherapy alone or in combination with other treatments. Further studies investigating the development of effective agents for use in treatment-resistant patients are required.

show abstract

Section: Discussionmentioning

confidence: 99%

“…CNS relapse occurs in between 5 and 16% of patients with primary breast DLBCL (4,5,11,13). Increased rates of CNS relapse (3-year cumulative incidence, 23.6 vs. 1.4%; P<0.001) have been observed in a matched-pair analysis of primary breast and nodal DLBCL following treatment with R-CHOP (22).…”

Section: Discussionmentioning

confidence: 99%

Primary breast lymphoma: A single center study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In Burkitt's lymphoma, radiotherapy has no function even if it's local disease. Patients with high-grade lymphomas that were refractory or relapsed after initial treatment should be considered for bone marrow transplantation 11 .…”

Section: Discussionmentioning

confidence: 99%

Non-Hodgkin lymphoma in breast: case report

Pedrini¹,

Schorr²,

Munaretto³

et al. 2017

Rev. Bras. Mastol. (Impr.)

View full text Add to dashboard Cite

The primary breast lymphoma is a rare tumor, accounting for up to 0.5% of breast cancers. Most primary breast lymphoma is presented as non-Hodgkin lymphoma, the B-cells lymphoma is the most common, and Burkitt lymphoma is the most aggressive. We report the case of a 24-year-old female patient, with global, progressive and rapid increase of the right breast during 30 days with reaction to insect bite and progressive weight loss, fatigue, fever and nocturne sweating. An echo-guided core biopsy was held with injury and showed an atypical lymphoid proliferation, suggestive of high-grade non-Hodgkin lymphoma. Immunohistochemistry confirmed non-Hodgkin lymphoma, B immunophenotype, Burkitt type. Also, the diagnosis of HIV infection was performed during hospitalization. Patient started with multidrug chemotherapy scheme and antiretroviral therapy. Burkitt lymphoma is an exceptionally aggressive subtype and can affect the central nervous system and gastrointestinal tract, and treatment consists of chemotherapy with multiple agents as soon as possible. Radiotherapy has no function in the Burkitt type cases, even in case of only local disease. RESUMO

show abstract

“…The optimal treatment of PBL remains undefined. [1,[3][4][5][6][7][8][9][10] On the other side, the use of rituximab has brought a new era in the treatment of lymphoma. In combination with chemotherapy, rituximab has well-proved efficacy in treatment of DLBCL.…”

mentioning

confidence: 99%

“…[1][2][3] The most common type of pathology of PBL is diffuse large B-cell lymphoma (DLBCL). The optimal treatment of PBL remains undefined.…”

mentioning

confidence: 99%

Primary breast lymphoma: A single-institute experience in Taiwan

Ou¹,

Shih²,

Wang³

et al. 2014

Biomed J

View full text Add to dashboard Cite

Background:Breast is an uncommon location of lymphoma involvement. The most common type of primary breast lymphoma (PBL) is diffuse large B-cell lymphoma (DLBCL). Rituximab is the widely used monoclonal antibody against CD20+ B-cell lymphoma, especially DLBCL. We aimed to analyze the clinical features, prognostic factors, and treatment outcome with or without rituximab in primary breast DLBCL. Methods:We retrospectively analyzed patients diagnosed with PBL from October 1987 to March 2012 in our hospital, excluding metastasis by whole-body computed tomography and bone marrow study. Results:Twenty-three patients were diagnosed with PBL. All were females. Eighteen patients were stage IE and five were stage IIE according to the Ann Arbor staging system. Two patients had lymphoma other than DLBCL. The median age of primary breast DLBCL patients was 48 years (range 27-79). Two were excluded from the analysis due to refusal or ineligibility for chemotherapy. No significant prognostic factor was found. Patients receiving chemotherapy with (RC) or without (C) rituximab were not significantly different in the 5-year overall survival (RC: 57.1%; C: 58.3%; p = 0.457) or progression-free survival (RC: 57.1%; C: 50.0%; p = 0.456). A high incidence of relapse in the central nervous system (CNS) (17.6%) was observed. Conclusions: In accordance with prior literature reports, our Taiwanese cohort of primary breast DLBCL seemed younger than those reported in Japan, Korea, and Western societies. Relapse in the CNS was not uncommon. The benefit of rituximab in addition to chemotherapy was not statistically significant. Treatment modality remained to be defined by further large-scale studies. (Biomed J 2014;37:321-325)

show abstract

Primary breast lymphoma: Patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study

Abstract: Background: To asses the clinical profile, treatment outcome and prognostic factors in primary breast lymphoma (PBL).

Cited by 140 publications

References 32 publications

Primary breast lymphoma: A single center study

Primary breast lymphoma: A single center study

Non-Hodgkin lymphoma in breast: case report

Primary breast lymphoma: A single-institute experience in Taiwan

Contact Info

Product

Resources

About